Search clinical trials for: Cosentyx (EU-licensed)

Total 341 results

Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects

Psoriasis

China
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects

Rheumatoid Arthritis

China
Bio-Thera Solutions

Completed

Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects

Severe Asthma

China
Fresenius Kabi SwissBioSim GmbH

Completed

Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

Healthy

New Zealand
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects

Psoriasis

China
Prestige Biopharma Limited

Recruiting

To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects

Healthy Volunteers

Spain
Alteogen, Inc.
Cristália Produtos Químicos Farmacêuticos Ltda.

Completed

A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects

Healthy
mAbxience Research S.L.

Completed

A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva

Healthy Volunteers

Poland
Bio-Thera Solutions

Active, not recruiting

Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients

Plaque Psoriasis

China
Celltrion

Completed

Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects

Healthy Subjects

New Zealand
Bio-Thera Solutions

Completed

Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Rheumatoid Arthritis

China
Fresenius Kabi SwissBioSim GmbH

Completed

MSB11022 in Healthy Subjects

Healthy Subjects
Celltrion

Completed

To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects

Healthy

Korea, Republic of
Shanghai Henlius Biotech

Completed

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects

Healthy

China
Novartis Pharmaceuticals

Recruiting

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis (SPARROW)

Moderate-to-severe Plaque Psoriasis

Russian Federation
Novartis Pharmaceuticals

Available

Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa (HS)
University of California, San Francisco
Novartis Pharmaceuticals

Completed

Immunologic Response to Secukinumab in Plaque Psoriasis

Psoriasis

United States
Novartis Pharmaceuticals

Active, not recruiting

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

Psoriasis Vulgaris | Pustular Psoriasis | Psoriatic Arthritis

Japan
Novartis Pharmaceuticals

Active, not recruiting

A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

Moderate to Severe Chronic Plaque Psoriasis

China
Beth Israel Deaconess Medical Center
Novartis Pharmaceuticals

Terminated

Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

Necrobiosis Lipoidica Diabeticorum

United States
Massachusetts General Hospital
Novartis

Withdrawn

A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

Discoid Lupus Erythematosus

United States
Diamant Thaci
Novartis

Completed

Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients (BIOMARKER)

Psoriasis Vulgaris

Germany
Tanja Todberg, MD

Unknown

Anti-IL-17 a New Treatment for Contact Dermatititis

Allergic Contact Dermatitits

Denmark
Gan and Lee Pharmaceuticals, USA

Completed

PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males

Diabetes Mellitus

Germany
Novartis Pharmaceuticals

Completed

A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China (UNMASK2)

Psoriasis

China
Novartis Pharmaceuticals

Completed

An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source

Plaque Psoriasis

United States
Mayo Clinic

Completed

Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

PITYRIASIS RUBRA PILARIS

United States
Narrows Institute for Biomedical Research
Novartis

Unknown

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

Psoriasis Vulgaris

United States
Tufts Medical Center

Completed

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Chinese University of Hong Kong

Completed

PsA Secukinumab XCT Structural Progression Study

Psoriatic Arthritis

Hong Kong
Jinnah Postgraduate Medical Centre

Completed

Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.

Plaque Psoriasis

Pakistan
Amgen

Recruiting

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Melanoma

Italy, Spain, South Africa, Japan, Serbia, Bosnia and Herzegovina, United States, Argentina, Chile, Georgia, Malaysia, Korea, Republic of, France, Germany, Croatia, Thailand, Brazil, Taiwan, Romania, Mexico, Netherlands
Seqirus

Active, not recruiting

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Influenza, Human

Philippines, United States, Germany, Pakistan, Canada, Estonia, Denmark, United Kingdom
University of Pennsylvania
Novartis

Recruiting

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Psoriasis

United States
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects

Psoriatic Arthritis

China
Kashiv BioSciences, LLC

Completed

To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects

Healthy

India
Celltrion

Completed

To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects

Healthy

Australia
Vrije Universiteit Brussel
University of British Columbia; University of Coimbra; Amsterdam UMC, location... and other collaborators

Not yet recruiting

International Study to Evaluate a Navigation Program for Older People With Cancer and Their Family Caregivers (EU NAVIGATE Study) (EU NAVIGATE)

Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative
Celltrion

Completed

To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin

Healthy

Korea, Republic of
University of Oxford
Malaria Research and Training Center, Bamako, Mali

Active, not recruiting

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Malaria

Mali, United Kingdom
Novartis Pharmaceuticals

Withdrawn

Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population

Psoriasis
University of North Carolina, Chapel Hill

Completed

A Study of Inhalation of 20,000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers (IRB 09-0259)

Healthy | Cigarette Smoking

United States
Ruhr University of Bochum

Completed

Tachosil for the Prevention of Symptomatic Lymph Cysts

Cervical Cancer | Endometrial Cancer

Austria, Germany
AbbVie

Completed

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
Vanderbilt University

Completed

Family-Centered Songwriting in Pediatric Palliative Care

Cognitive Impairment

United States
Professor Mikkel Østergaard
Novartis Healthcare A/S

Unknown

Treat-to-target With Secukinumab in Axial Spondyloarthritis (TRACE)

Ankylosing Spondylitis | Axial Spondyloarthritis

Denmark
Fresenius Kabi SwissBioSim GmbH

Completed

MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis

Hungary, Serbia, Georgia, Russian Federation, Slovakia, Czechia, Bulgaria, Moldova, Republic of, Poland
Janssen Research & Development, LLC

Completed

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4

Healthy

Belgium
Celltrion

Recruiting

A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects

Healthy Subjects

Korea, Republic of
ISU Abxis Co., Ltd.

Completed

A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers

Gaucher Disease

Australia

3

Subscribe